正在寻找类似产品? 访问 产品对比指南
一般描述
MISSION ® 荧光素酶 shRNA 对照载体是一个 7,091 碱基对的慢病毒质粒载体，含有靶向来自 Photinus pyralis 荧光素酶的 shRNA 序列（GenBank 登记号：M15077)。荧光素酶 shRNA 对照载体在使用表达萤火虫荧光素酶的细胞系的实验中作为阳性敲除对照十分有用。其也可作为阴性对照载体。
氨苄西林和嘌呤霉素抗生素抗性基因分别在细菌或哺乳动物细胞中提供选择。此外，通过与相容的包装质粒共转染，可在包装细胞 (HEK293T) 中产生自我失活复制无能的病毒颗粒，MISSION ® 慢病毒包装混合物（产品编号：SHP001）。荧光素酶 shRNA 对照载体以 10μg 质粒 DNA，溶于 Tris-EDTA (TE) 缓冲液中，浓度为 500 ng/μl.
氨苄西林和嘌呤霉素抗生素抗性基因分别在细菌或哺乳动物细胞中提供选择。此外，通过与相容的包装质粒共转染，可在包装细胞 (HEK293T) 中产生自我失活复制无能的病毒颗粒，MISSION ® 慢病毒包装混合物（产品编号：SHP001）。荧光素酶 shRNA 对照载体以 10μg 质粒 DNA，溶于 Tris-EDTA (TE) 缓冲液中，浓度为 500 ng/μl.
应用
想要查看更多应用数据、实验方案和载体图谱，请访问 sigma.com/shrna。
法律信息
使用本产品需遵守一个或多个许可协议。有关详细信息，请参阅http://sigmaaldrich.com/missionlicense。
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
10 - Combustible liquids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
常规特殊物品
Vajiheh Neshati et al.
Applied biochemistry and biotechnology, 186(1), 245-255 (2018-03-27)
Since the adult mammalian heart has limited regenerative capacity, cardiac trauma, disease, and aging cause permanent loss of contractile tissue. This has fueled the development of stem cell-based strategies to provide the damaged heart with new cardiomyocytes. Bone marrow-derived mesenchymal
Deepak Bararia et al.
Nature communications, 7, 10968-10968 (2016-03-24)
CCAAT/enhancer-binding protein alpha (C/EBPα) is an essential transcription factor for myeloid lineage commitment. Here we demonstrate that acetylation of C/EBPα at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPα DNA-binding
Islands of spatially discordant APD alternans underlie arrhythmogenesis by promoting electrotonic dyssynchrony in models of fibrotic rat ventricular myocardium.
Majumder R
Scientific Reports, 6 (2016)
Victoria J Gennaro et al.
BMC cancer, 19(1), 258-258 (2019-03-25)
The oncoprotein MYC has the dual capacity to drive cell cycle progression or induce apoptosis, depending on the cellular context. BAG1 was previously identified as a transcriptional target of MYC that functions as a critical determinant of this cell fate
Stephen C Mack et al.
Nature, 553(7686), 101-105 (2017-12-21)
Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持